Humanis Takes Critical Step in Neurology: New Treatment for Parkinson's Psychosis

A significant advance has been achieved in the treatment of psychosis associated with Parkinson's disease. Humanis has introduced a new therapy for treating hallucinations and delusions seen in Parkinson's disease-related psychosis in Turkey for the first time after the United States. This innovative approach, which is not yet available in European Union countries, aims to fill an important gap in neurology and psychiatry.

As Parkinson's disease progresses, some patients may experience psychotic symptoms such as hallucinations and delusions, a condition that can seriously affect both patients' quality of life and the care burden on family members. Parkinson's disease-related psychosis stands out as a clinically sensitive area of management with limited treatment options. Through Humanis's initiative, the new therapy introduced to medical practice in Turkey for the first time after the United States aims to improve the quality of life for patients and their relatives.

"We are proud to be offering this therapy in Turkey for the first time after the United States"
Dr. Yalçın Yaşin, Chief Commercial Operations Officer at Humanis, made the following statement: "We know that Parkinson's disease is not limited to motor symptoms alone. Psychotic symptoms can be quite challenging for both patients and their families. We are greatly pleased to introduce a new therapy in this field to medical practice in Turkey. We see it as our responsibility to closely monitor scientific developments and bring solutions that provide real benefit to patients to our country. In line with our patient-centered approach, we address not only the disease but also the quality of life of patients and their families from a holistic perspective; we continue to generate sustainable value in healthcare." he said.